Traws Pharma, Inc. Receives Nasdaq Non-Compliance Notice Over Minimum Bid Price Requirement
Key Highlights:
- Traws Pharma, Inc. (NASDAQ: TRAW) has received a notification letter from the Nasdaq Stock Market LLC for non-compliance with the minimum bid price requirement.
- The company’s common stock has traded below \$1.00 per share for at least 30 consecutive business days.
- Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance.
- No immediate impact on the company’s listing status; trading remains effective for now.
- If compliance is not regained, the company may face delisting, subject to appeal rights.
Detailed Article
Traws Pharma, Inc. (the “Company”), listed on The Nasdaq Stock Market LLC under the ticker symbol TRAW, announced that it has received an important notification letter from the Nasdaq Listing Qualifications Department on July 29, 2026. The letter stated that the Company is not currently in compliance with Nasdaq Listing Rule 5550(a)(2), which requires that the closing bid price for listed securities remain at or above \$1.00 per share.
The trigger for this notice was that Traws Pharma’s common stock closed below \$1.00 per share for a period of at least 30 consecutive business days. This is a critical regulatory threshold for all companies listed on the Nasdaq Capital Market, and failure to comply may result in the delisting of the company’s shares from the exchange.
Importantly for shareholders, the receipt of this notice does not have any immediate effect on the listing or trading of Traws Pharma’s common stock. The Company’s shares will continue to trade as normal on Nasdaq under the symbol TRAW while the Company seeks to regain compliance.
Under Nasdaq’s rules, Traws Pharma now has a compliance period of 180 calendar days, expiring on January 25, 2027, to bring its share price back above \$1.00 for a minimum of 10 consecutive business days. If the Company fails to meet this threshold within the initial compliance period, it may be eligible for an additional 180-day extension, provided it meets certain other continued listing requirements.
Should Traws Pharma not regain compliance within the allotted time frame (including any possible extension), Nasdaq will issue a formal notice of delisting. At that point, the Company would have the right to appeal the delisting determination to a Nasdaq hearings panel. However, there can be no assurance that the Company will be able to regain compliance within the 180-day period, secure an additional extension, or ultimately avoid delisting.
What Shareholders Need to Know:
- This notice is considered price-sensitive information and may affect investor sentiment and share price volatility.
- The risk of potential delisting could impact the liquidity and marketability of Traws Pharma’s shares.
- The Company’s management is actively monitoring the situation and evaluating options to regain compliance, which may include corporate actions such as a reverse stock split or other measures.
- If the Company regains compliance at any time during the compliance period, the matter will be closed by Nasdaq with no further action.
Investors are advised to closely monitor further announcements from Traws Pharma regarding its compliance efforts and any updates on its Nasdaq listing status.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The information contained here is based on the company’s public filings as of the date indicated and may be subject to change without notice.
